{"id":51775,"date":"2025-12-22T20:40:01","date_gmt":"2025-12-22T12:40:01","guid":{"rendered":"https:\/\/flcube.com\/?p=51775"},"modified":"2025-12-22T20:40:02","modified_gmt":"2025-12-22T12:40:02","slug":"simcere-zaiming-licenses-adc-sim0613-to-ipsen-in-1-06-billion-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51775","title":{"rendered":"Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal"},"content":{"rendered":"\n

Simcere Pharmaceutical Group Limited’s<\/strong> (HKG: 2096<\/a>) subsidiary Simcere Zaiming<\/strong> entered into an exclusive global licensing agreement with Ipsen<\/strong> for SIM0613<\/strong>, a next\u2011generation LRRC15\u2011targeted antibody\u2011drug conjugate (ADC)<\/strong>. The deal, valued at up to $1.06\u202fbillion<\/strong> , marks Simcere Zaiming’s third out\u2011licensing<\/strong> in 2025, pushing Simcere’s cumulative transaction value to nearly $3.4\u202fbillion<\/strong> .<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Component<\/th>Details<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Simcere Zaiming (Simcere Pharmaceutical Group subsidiary)<\/td><\/tr>
Licensee<\/strong><\/td>Ipsen (French biopharmaceutical company)<\/td><\/tr>
Asset<\/strong><\/td>SIM0613 (LRRC15\u2011targeted ADC)<\/td><\/tr>
Territory<\/strong><\/td>Global (excluding Greater China)<\/td><\/tr>
Deal Value<\/strong><\/td>Up to $1.06\u202fbillion<\/strong> : upfront + development\/regulatory\/commercial milestones + tiered royalties<\/td><\/tr>
Cumulative Value<\/strong><\/td>Simcere’s 2025 out\u2011licensing totals nearly $3.4\u202fbillion<\/strong> across 4 innovative drugs<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile<\/h2>\n\n\n\n
Attribute<\/th>SIM0613<\/th>Competitive Advantage<\/th><\/tr><\/thead>
Target<\/strong><\/td>LRRC15 (highly expressed on solid tumors and CAFs)<\/td>Minimal expression in normal cells<\/td><\/tr>
Mechanism<\/strong><\/td>ADC binds LRRC15 \u2192 endocytosis \u2192 cytotoxic payload release<\/td>Selective tumor cell killing<\/td><\/tr>
Features<\/strong><\/td>Engineered for deep tumor and CAF penetration<\/td>Addresses stromal barriers in solid tumors<\/td><\/tr>
Preclinical Data<\/strong><\/td>Significant anti\u2011tumor activity across multiple in vivo models<\/td>Best\u2011in\u2011class potential<\/td><\/tr>
Innovation<\/strong><\/td>First LRRC15\u2011targeted ADC to enter global licensing<\/td>Novel target in ADC space<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n